Summary of Pelthos Therapeutics FY Conference Call (March 23, 2026) Company Overview - **Company**: Pelthos Therapeutics (NYSEAM:PTHS) - **Lead Product**: ZELSUVMI, a topical nitric oxide releasing product for treating molluscum contagiosum in patients aged one year and older [5][7] Key Points Company Background and Capitalization - Pelthos was formed from a merger with Channel Therapeutics on July 1, 2025, after raising $50 million through a PIPE [5] - The company trades on the NYSE under the ticker PTHS, with a current market cap of approximately $200 million [6] Product Information - **ZELSUVMI**: - First FDA-approved at-home treatment for molluscum contagiosum, allowing for daily application over 12 weeks [8] - Addresses a significant unmet need as traditional treatments involve painful procedures [7][10] Financial Performance - Prescription volume increased by 129% from Q3 to Q4, with net revenue rising from $7.1 million in Q3 to $9.1 million in Q4 [13][14] - The company has over 4,200 unique prescribers since the product launch [14] - Payer access is favorable, with 70% of prescriptions covered by commercial insurance and 99% by Medicaid [15][16] - Gross to net ratio improved from 25.3% in Q3 to 28.7% in Q4, with expectations to reach mid- to upper 30s% in 2026 [18] Sales Strategy and Market Access - The sales force is approximately 64 representatives, focusing on both dermatologists and pediatricians [19] - The company plans to leverage existing sales channels for new products, Xepi and Xeglyze, which target pediatric conditions [20][25] New Product Acquisitions - **Xepi**: - Targets impetigo, with a significant market need due to resistance to current treatments [21] - Expected to launch in early 2027 [24] - **Xeglyze**: - Aimed at treating head lice, with a unique dual-action formula [22] - Planned launch in the latter half of Q2 2027 [25] Future Outlook - Revenue guidance for ZELSUVMI is projected at $175 million by 2028, with a current consensus estimate of just over $60 million for the year [57] - The company is comfortable with its cash position, having raised $50 million in equity and additional funds through convertible debt [55][56] Intellectual Property and Market Exclusivity - ZELSUVMI has patent protection until 2035, with potential extensions into 2037 [40] - Xepi and Xeglyze have exclusivity until early 2032 and 2034, respectively [41] Strategic Focus - The primary focus remains on successfully launching ZELSUVMI, with plans to evaluate additional indications for the NITRICIL platform in the future [47][49] Additional Insights - The company emphasizes the importance of executing its current business plan before pursuing further acquisitions or expansions [47] - There is a noted prevalence of "super lice," which enhances the market potential for Xeglyze [22]

Summary of Pelthos Therapeutics FY Conference Call Company Overview - **Company Name**: Pelthos Therapeutics (NYSEAM:PTHS) - **Industry**: Biopharmaceuticals, specifically focused on pediatric cutaneous infectious diseases - **Ticker Symbol**: PTHS - **Market Capitalization**: Approximately $200 million [4] - **Shares Outstanding**: 8.9 million common shares [4] Key Products and Developments - **Lead Product**: ZELSUVMI, launched in July 2025, indicated for the treatment of molluscum contagiosum in patients aged 1 year and older [3][7] - **Recent Acquisitions**: - **Xepi**: Acquired in late 2025, expected launch in late 2026, treats impetigo [3][29] - **Xeglyze**: Acquired for $1.8 million, FDA-approved for head lice treatment, expected launch in mid-2027 [30][31] Financial Highlights - **Cash Position**: $14.2 million at Q3 close, raised an additional $18 million in a convertible note [4] - **Revenue Generation**: - Q3 2025: 2,700 units of ZELSUVMI dispensed, generating $7.1 million in net revenue [24] - Q4 2025: 129% growth in units quarter-over-quarter [24] - Anticipated gross-to-net (GTN) in Q4 expected to rise to the high 30% range [25] Market Strategy and Sales Performance - **Sales Force**: Initially launched with 50 representatives, expanded to 64 territories by March [21][22] - **Target Audience**: Focus on dermatologists, pediatric dermatologists, and pediatricians, covering approximately 10,000 top molluscum treaters [22] - **Digital Marketing**: Successful YouTube promotional video with over 3.5 million views [23] Clinical Insights and Product Efficacy - **ZELSUVMI Efficacy**: - B-SIMPLE4 trial showed about one-third of patients achieved complete clearance at 12 weeks [19] - 80% of parents found the treatment clinically meaningful even without complete clearance [20] - **Safety Profile**: Common side effects include mild application site pain (12%) and moderate pain (6%) [17] Market Challenges and Opportunities - **Molluscum Contagiosum**: High prevalence among children, with 73% of affected children going untreated [10] - **Treatment Landscape**: Traditional treatments often require multiple painful office visits; ZELSUVMI offers a home-based solution [16][17] - **Resistance Issues**: Concerns over mupirocin resistance in treating impetigo, presenting an opportunity for Xepi [30] Management Team and Experience - **CEO**: Over 30 years in the pharmaceutical industry, with a history of successful exits [5] - **Board Composition**: Includes experienced executives from various pharmaceutical companies, enhancing strategic direction [6] Future Outlook - **Product Pipeline**: Focus on maximizing ZELSUVMI's market potential before launching Xepi and Xeglyze [32] - **Potential Collaborations**: Opportunities to work with Ligand on clinical stage programs for the NITRICIL platform [37] - **Financial Position**: Strong capital position to support growth and potential acquisitions [36] Conclusion Pelthos Therapeutics is positioned for growth with its innovative product ZELSUVMI, a strong management team, and strategic acquisitions. The company is focused on addressing unmet needs in pediatric infectious diseases while navigating market challenges and leveraging digital marketing strategies for enhanced outreach.